Statin-associated myopathy.

Area of Science:

• Pharmacology
• Toxicology
• Clinical Medicine

Background:

• Statins, HMG-CoA reductase inhibitors, are widely used for cholesterol management.
• These drugs are associated with a spectrum of skeletal muscle complaints, ranging from myalgia to rhabdomyolysis.
• Understanding these adverse effects is crucial for patient safety and effective lipid-lowering therapy.

Purpose of the Study:

• To provide a clinical summary of statin-associated myopathy.
• To discuss potential mechanisms underlying statin-induced muscle injury.
• To update reports on statin-associated rhabdomyolysis using FDA data.

Main Methods:

• Literature review of statin myopathy articles via PubMed (through November 2002).
• Review of statin clinical trials, case series, and reviews (PubMed through January 2003).
• Analysis of FDA MEDWATCH adverse event reports for statin-associated rhabdomyolysis (January 1990 - March 2002).

Main Results:

• Muscle problems are rare in statin clinical trials.
• The FDA MEDWATCH system documented 3339 cases of statin-associated rhabdomyolysis, with cerivastatin being most implicated.
• Data on less severe muscle symptoms (pain, weakness) suggest a 1-5% prevalence; risk factors and drug interactions (e.g., gemfibrozil) can exacerbate adverse effects.

Conclusions:

• Statin-associated myopathy encompasses a range of muscle issues, including rare but severe rhabdomyolysis.
• Factors like organ dysfunction, comorbidities, and drug interactions significantly influence the risk of myopathy.
• While mechanisms are not fully elucidated, statins may impair myocyte maintenance by reducing regulatory protein production.